/
Neurology
Mild to Moderate Alzheimer's Disease
7
Pipeline Programs↗
8
Active Trials↗
36
Companies Involved↗
Mild to Moderate Alzheimer's Disease is an early-stage landscape with 7 programs across 36 companies. The most active players are NSC-Therapeutics, Roche. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 24
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
5 of 6 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 86% of 7 pipeline programs.
Analysis
Trial Status
139
clinical trials
Completed98 · 71%
Terminated17 · 12%
Unknown status13 · 9%
Not yet recruiting5 · 4%
Recruiting3 · 2%
Withdrawn2 · 1%
Other1 · 1%
Clinical Trials
Trial Activity
139 trials
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)